iBio, Inc. Cash Flow Statement
IBIO|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
iBio, Inc. used $19M in operating cash flow and negative free cash flow of $19M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.36 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$24.9M | -$65.0M | -$50.3M | -$23.2M | -$16.4M | -$17.6M | -$16.1M | -$14.5M | -$9.8M | -$6.6M | -$3.7M | -$6.2M | -$5.7M |
| Depreciation & Amortization | $638.0K | $674.0K | $2.3M | $472.0K | $282.0K | $179.0K | $179.0K | $1.3M | $577.0K | $5.0K | $3.0K | $2.0K | $7.0K |
| Operating Cash Flow | -$18.6M | -$30.4M | -$37.5M | -$30.1M | -$13.3M | -$14.0M | -$13.5M | -$13.2M | -$8.1M | -$4.7M | -$4.1M | -$4.8M | -$6.0M |
| Capital Expenditures | $210.0K | $5.7M | $7.3M | $4.9M | $1.1M | $920.0K | $934.0K | $1.3M | $68.0K | $13.0K | $4.0K | $7.0K | $1.0K |
| Free Cash Flow | -$18.8M | -$36.2M | -$44.8M | -$35.0M | -$14.4M | -$14.9M | -$14.4M | -$14.5M | -$8.1M | -$4.7M | -$4.1M | -$4.9M | -$6.0M |
| FCF Margin | -8339.6% | - | -2378.5% | -1475.5% | -880.5% | -738.1% | -3246.4% | -3676.7% | -858.6% | -256.0% | -2009.8% | -482.2% | -470.7% |